1. Safe anti-programmed cell death-1 rechallenge with antibody switching after immune-related adverse events: brief communication.
- Author
-
Aya F, González-Navarro EA, Martínez C, Carcelero E, and Arance A
- Subjects
- Aged, Chemical and Drug Induced Liver Injury etiology, Female, Humans, Male, Melanoma drug therapy, Antibodies, Monoclonal, Humanized therapeutic use, Drug Substitution, Immune Checkpoint Inhibitors therapeutic use, Nephritis chemically induced, Nivolumab therapeutic use
- Abstract
Aim: To evaluate the safety of rechallenge with a different anti-PD-1 antibody after an immune-related adverse event (irAE) that has prompted the discontinuation of anti-PD-1 therapy. Patients & methods: We describe two patients with metastatic melanoma who developed potentially disabling and early irAEs following anti-PD-1 treatment. Therapy was discontinued and toxicities resolved with corticosteroids. Results: Rechallenge switching to an alternative anti-PD-1 antibody did not lead to a new or recurrent irAE. Conclusion: Switching to a different anti-PD-1 antibody when resuming therapy after an irAE might be a safe strategy and warrants further investigation. Structural and biological differences between antibodies might explain the different safety outcomes.
- Published
- 2021
- Full Text
- View/download PDF